The laminin binding integrins (LB integrins) play critical roles during carcinoma initiation, progression, metastasis, and survival. Among the different integrins, only the LB integrins (a6?1, a6?4, a3?1, a7?1) undergo palmitoylation, and associate closely with tetraspanin CD151, which enables their recruitment into tetraspanin-enriched microdomains. In this context, CD151 and other associated partner proteins regulate LB integrin-dependent cell spreading, motility, signaling, adhesion strengthening, EGFR collaboration, and lateral diffusion, on epithelial, endothelial and other cell types. CD151 itself also associates positively with tumor cell malignancy, in multiple carcinoma types. In this regard, our CD151 knockout mice are deficient in hosting primary and/or secondary tumor growth in ectopic tumor injection models, and in a spontaneous mouse mammary tumor model. This host defect in CD151-null mice is due, at least in part, to a deficit in pathological angiogenesis. Tumor cell CD151 also notably supports tumor progression, as seen in both orthotopic and ectopic xenograft models. Consequently, we hypothesize that tetraspanin CD151 uses extracellular, intracellular, and lateral association sites to link LB integrins to tetraspanin-enriched microdomains, which contributes to the specialized functional properties of laminin-binding integrins, and promotes tumor cell malignancy. To test this model, we will carry out a comprehensive analysis of LB integrin and CD151-associated molecules, cytoskeletal interactions, and dominant negative mutations, both in vitro, and in vivo during primary and secondary tumor growth.
In Aim 1 we will use a differential mass spectrometry approach to identify additional membrane and cytoskeletal partner proteins for LB integrins, as well as possible compensating proteins, which preferentially associate with LB integrins when CD151 is absent.
In Aim 2, we will sort out positive and negative effects, exerted by the cytoskeleton on LB integrin functions, and on the EGFR.
Aim 3 will be used to amplify disruption of LB integrin functions, using a) dominant negative mutant forms of CD151, b) knockdown of proteins that may compensate for CD151 absence, and c) knockdown of supporting proteins.
In Aim 4, we will learn the extent to which LB integrin complexes contribute to primary tumor growth in vivo, using transgenic mouse models of spontaneous mammary cancer.
Aim 5 will study, in both tumor and host, the effects of LB integrin complex disruption on metastasis.

Public Health Relevance

LB integrins and CD151 have been implicated in tumor progression at many levels, including tumor initiation, primary growth, and metastasis, through tumor effects and host animal effects. Our preliminary results suggest that disruption of LB integrin complexes, largely by deleting or modifying CD151, profoundly affects tumor progression, while minimally affecting normal physiology. Our proposed studies of this alternative method for modulating LB integrins should lead to novel strategies for therapeutic intervention in breast cancer and other cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042368-28
Application #
8462206
Study Section
Tumor Microenvironment Study Section (TME)
Program Officer
Snyderwine, Elizabeth G
Project Start
1986-05-01
Project End
2014-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
28
Fiscal Year
2013
Total Cost
$278,166
Indirect Cost
$117,878
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Hemler, Martin E (2014) Tetraspanin proteins promote multiple cancer stages. Nat Rev Cancer 14:49-60
Knoblich, Konstantin; Wang, Hong-Xing; Sharma, Chandan et al. (2014) Tetraspanin TSPAN12 regulates tumor growth and metastasis and inhibits *-catenin degradation. Cell Mol Life Sci 71:1305-14
Yang, Xiuwei H; Mirchev, Rossen; Deng, Xinyu et al. (2012) CD151 restricts the ýý6 integrin diffusion mode. J Cell Sci 125:1478-87
Wang, Hong-Xing; Li, Qinglin; Sharma, Chandan et al. (2011) Tetraspanin protein contributions to cancer. Biochem Soc Trans 39:547-52
Takeda, Yoshito; Li, Qinglin; Kazarov, Alexander R et al. (2011) Diminished metastasis in tetraspanin CD151-knockout mice. Blood 118:464-72
Yang, Xiuwei H; Flores, Ludmila M; Li, Qinglin et al. (2010) Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 70:2256-63
Kolesnikova, Tatiana V; Kazarov, Alexander R; Lemieux, Madeleine E et al. (2009) Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo. Neoplasia 11:77-86, 4p following 86
Yang, Xiuwei H; Richardson, Andrea L; Torres-Arzayus, Maria I et al. (2008) CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Cancer Res 68:3204-13
Hemler, Martin E (2008) Targeting of tetraspanin proteins--potential benefits and strategies. Nat Rev Drug Discov 7:747-58
Sharma, Chandan; Yang, Xiuwei H; Hemler, Martin E (2008) DHHC2 affects palmitoylation, stability, and functions of tetraspanins CD9 and CD151. Mol Biol Cell 19:3415-25

Showing the most recent 10 out of 53 publications